With the emergence and long-term Impact of COVID-19, Global Radiotheranostics Market to reach USD 20.67 Billion by 2030
Bizwit Research & Consulting LLP’s Recent Analysis on Global Radiotheranostics Market is poised to raise up to USD 20.67 Billion by 2030. Radiotheranostics refers to the field of medicine that combines the therapeutic and diagnostic application of radiopharmaceuticals enabling personalized treatment strategies by using targeted radiation therapy and imaging techniques. The Radiotheranostics market is being driven by factors such as the Increasing prevalence of cancer cases and the rising adoption of injectable radiopharmaceuticals. In addition, increasing the approvals of new radiotheranostics agents and increasing public-private funding for research may create lucrative opportunities for the market. However, market expansion may hinder due to the high cost involved in research and development.
Geographically, the global Radiotheranostics market has been segmented into North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa (MEA). North America holds the major share in radio theranostics market due to the rising overweight population and also rising adoption of large number of market players. Asia Pacific consider fastest growing market due to its large patient base and high investing nuclear medicine along with that rising prevalence of cancer.
The global Radiotheranostics market is highly competitive owing to the presence of several key manufacturers such as Novartis AG, Bayer AG, Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited., ITM Isotope Technologies Munich SE, Life Molecular Imaging., RadioMedix Inc. and others.
For further analysis on this or to request a sample copy of this report, please click the link mentioned below:
Global Radiotheranostics Market Size study & Forecast, by Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others), by Approach (Targeted Therapeutic, Targeted Diagnostic), by Application (Oncology, Non Oncology) by and Regional Analysis, 2023-2030
Key findings of the study suggest:
- Global Radiotheranostics Market is anticipated to grow with a healthy growth rate of more than 13.46% over the forecast period 2023-2030.
- In the Radiosotope segment, Lutetium-177 emerged out as the leading market segment in 2022.
- In the Approach segment, Targeted Therapeutic emerged out as the leading market segment in 2022.
- In the Application segment, Oncology emerged as the leading market segment in 2022.
- North America is anticipated to drive regional growth Owing to rising continuous innovation in Radiotheranostics products, rising overweight population and also rising adoption of large number of market players.
- Asia-Pacific is expected to grow at higher rate followed by North America during 2023-2030.
Bizwit Research & Consulting has considered following segments for the study:
- 18F with Y-90
- Targeted Therapeutic
- Targeted Diagnostic
- Non Oncology
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
To get a sample of this report or to purchase a copy of the study, you can directly contact us at: firstname.lastname@example.org
Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. The company has a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. Bizwit incorporate big data, expert analysis, and huge industry database to deliver client focused business consulting reports. Our analysts perform unbiased measurement and assessment of market opportunities to comprehend detailed market forecast. Our team of key opinion leaders evaluates the market size, growth prospects, end-use, applications, value & supply chain and top vendors in the industry to help the clients to take conversant business decisions without any vague assumptions.
Global Business Development
Phone : +1 209 498-3066